

# Russell Dahl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3802983/publications.pdf>

Version: 2024-02-01

64  
papers

2,950  
citations

117453

34  
h-index

168136

53  
g-index

67  
all docs

67  
docs citations

67  
times ranked

4627  
citing authors

#	ARTICLE	IF	CITATIONS
1	A new target for Alzheimer's disease: A small molecule SERCA activator is neuroprotective in vitro and improves memory and cognition in APP/PS1 mice. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1591-1594.	1.0	39
2	Small molecule SUMOylation activators are novel neuroprotective agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 405-409.	1.0	10
3	Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 31-34.	1.0	32
4	A new target for Parkinson's disease: Small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 53-57.	1.4	39
5	Cytoprotective small molecule modulators of endoplasmic reticulum stress. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2382-2388.	1.4	4
6	Small Molecular Allosteric Activator of the Sarco/Endoplasmic Reticulum Ca <sup>2+</sup> -ATPase (SERCA) Attenuates Diabetes and Metabolic Disorders. <i>Journal of Biological Chemistry</i> , 2016, 291, 5185-5198.	1.6	137
7	Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure. <i>Nature Communications</i> , 2015, 6, 7229.	5.8	102
8	Dual-Specificity Phosphatase 3 Deficiency or Inhibition Limits Platelet Activation and Arterial Thrombosis. <i>Circulation</i> , 2015, 131, 656-668.	1.6	42
9	Design, Synthesis and Bioevaluation of an EphA2 Receptor-Based Targeted Delivery System. <i>ChemMedChem</i> , 2014, 9, 1403-1412.	1.6	31
10	Discovery of Enzyme Modulators via High-Throughput Time-Resolved FRET in Living Cells. <i>Journal of Biomolecular Screening</i> , 2014, 19, 215-222.	2.6	88
11	Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4308-4311.	1.0	22
12	Alamar blue reagent interacts with cell-culture media giving different fluorescence over time: Potential for false positives. <i>Journal of Pharmacological and Toxicological Methods</i> , 2014, 70, 195-198.	0.3	19
13	Identification of a selective inhibitor of murine intestinal alkaline phosphatase (ML260) by concurrent ultra-high throughput screening against human and mouse isozymes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1000-1004.	1.0	6
14	Design and Synthesis of Systemically Active Metabotropic Glutamate Subtype-2 and -3 (mGlu <sub>2/3</sub> ) Receptor Positive Allosteric Modulators (PAMs): Pharmacological Characterization and Assessment in a Rat Model of Cocaine Dependence. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4154-4172.	2.9	36
15	Pharmacological inhibition of PHOSPHO1 suppresses vascular smooth muscle cell calcification. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 81-91.	3.1	52
16	High-Throughput FRET Assay Yields Allosteric SERCA Activators. <i>Journal of Biomolecular Screening</i> , 2013, 18, 97-107.	2.6	74
17	High-Throughput Fluorescence Polarization Assay for Chemical Library Screening against Anti-Apoptotic Bcl-2 Family Member Bfl-1. <i>Journal of Biomolecular Screening</i> , 2012, 17, 350-360.	2.6	22
18	Endoplasmic reticulum protein BI-1 regulates Ca <sup>2+</sup> -mediated bioenergetics to promote autophagy. <i>Genes and Development</i> , 2012, 26, 1041-1054.	2.7	83

#	ARTICLE	IF	CITATIONS
19	Novel MT1-MMP Small-Molecule Inhibitors Based on Insights into Hemopexin Domain Function in Tumor Growth. <i>Cancer Research</i> , 2012, 72, 2339-2349.	0.4	122
20	Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9434-9445.	2.9	23
21	LYP inhibits T-cell activation when dissociated from CSK. <i>Nature Chemical Biology</i> , 2012, 8, 437-446.	3.9	118
22	Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation. <i>ACS Chemical Biology</i> , 2012, 7, 367-377.	1.6	31
23	Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 2427-2436.	2.9	79
24	A Gatekeeper Residue for NEDD8-Activating Enzyme Inhibition by MLN4924. <i>Cell Reports</i> , 2012, 1, 309-316.	2.9	75
25	Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation. <i>FASEB Journal</i> , 2012, 26, 766.12.	0.2	0
26	Potent, Selective, and Orally Available Benzoisothiazolone Phosphomannose Isomerase Inhibitors as Probes for Congenital Disorder of Glycosylation Ia. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3661-3668.	2.9	39
27	Design and Synthesis of an Orally Active Metabotropic Glutamate Receptor Subtype-2 (mGluR2) Positive Allosteric Modulator (PAM) That Decreases Cocaine Self-Administration in Rats. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 342-353.	2.9	44
28	Discovery of a Novel Series of Inhibitors of Lymphoid Tyrosine Phosphatase with Activity in Human T Cells. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1640-1654.	2.9	46
29	Inhibition of the Hematopoietic Protein Tyrosine Phosphatase by Phenoxyacetic Acids. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 113-118.	1.3	7
30	Design and NMR Studies of Cyclic Peptides Targeting the N-Terminal Domain of the Protein Tyrosine Phosphatase YopH. <i>Chemical Biology and Drug Design</i> , 2011, 77, 12-19.	1.5	5
31	Recent Progress in the Synthesis and Characterization of Group II Metabotropic Glutamate Receptor Allosteric Modulators. <i>ACS Chemical Neuroscience</i> , 2011, 2, 382-393.	1.7	46
32	Design, synthesis, and structure-activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 2582-2588.	1.4	14
33	Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts.. <i>Journal of Biological Chemistry</i> , 2011, 286, 43588.	1.6	0
34	An Optically Pure Apogossypolone Derivative as Potent Pan-Active Inhibitor of Anti-Apoptotic Bcl-2 Family Proteins. <i>Frontiers in Oncology</i> , 2011, 1, 28.	1.3	43
35	Phosphomannose Isomerase Inhibitors Improve N-Glycosylation in Selected Phosphomannomutase-deficient Fibroblasts. <i>Journal of Biological Chemistry</i> , 2011, 286, 39431-39438.	1.6	39
36	KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. <i>European Journal of Pharmacology</i> , 2010, 632, 93-102.	1.7	10

#	ARTICLE	IF	CITATIONS
37	Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 590-596.	1.4	21
38	Optimization of $\beta$ -ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4819-4824.	1.0	20
39	Inhibition of Bfl-1 with N-aryl maleimides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 6560-6564.	1.0	24
40	Efficient Access to Aminomannoside Derivatives via Formal [2+2] Cycloaddition of Triazolinediones and Tri-O-acetyl-d-glucal. <i>Synthesis</i> , 2010, 2010, 2292-2296.	1.2	1
41	Fully Automated Continuous Flow Synthesis of Highly Functionalized Imidazo[1,2-a] Heterocycles. <i>Organic Letters</i> , 2010, 12, 412-415.	2.4	87
42	The mGluR2 Positive Allosteric Modulator BINA Decreases Cocaine Self-Administration and Cue-Induced Cocaine-Seeking and Counteracts Cocaine-Induced Enhancement of Brain Reward Function in Rats. <i>Neuropsychopharmacology</i> , 2010, 35, 2021-2036.	2.8	72
43	Synthesis and Biological Evaluation of Apogossypolone Derivatives as Pan-active Inhibitors of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 8000-8011.	2.9	34
44	BI-97C1, an Optically Pure Apogossypol Derivative as Pan-Active Inhibitor of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4166-4176.	2.9	102
45	Chemical Biology Strategy Reveals Pathway-Selective Inhibitor of NF- $\kappa$ B Activation Induced by Protein Kinase C. <i>ACS Chemical Biology</i> , 2010, 5, 287-299.	1.6	11
46	Design, Synthesis, and Structure-Activity Relationships of 3-Ethynyl-1H-indazoles as Inhibitors of the Phosphatidylinositol 3-Kinase Signaling Pathway. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 8368-8375.	2.9	27
47	<i>In vivo</i> antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1218-1226.	1.9	72
48	Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 904-913.	1.9	58
49	Apogossypol Derivatives as Pan-Active Inhibitors of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4511-4523.	2.9	55
50	Discovery and Binding Studies on a Series of Novel Pin1 Ligands. <i>Chemical Biology and Drug Design</i> , 2009, 73, 369-379.	1.5	9
51	Discovery of 2-(5-nitrothiazol-2-ylthio)benzo[d]thiazoles as novel c-Jun N-terminal kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 2712-2717.	1.4	23
52	Design, Synthesis, and Structure-Activity Relationship of Substrate Competitive, Selective, and <i>In Vivo</i> Active Triazole and Thiadiazole Inhibitors of the c-Jun N-Terminal Kinase. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1943-1952.	2.9	71
53	Discovery and Validation of a Series of Aryl Sulfonamides as Selective Inhibitors of Tissue-Nonspecific Alkaline Phosphatase (TNAP). <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6919-6925.	2.9	95
54	Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1498-1501.	1.0	22

#	ARTICLE	IF	CITATIONS
55	The design and synthesis of novel Î±-ketoamide-based p38 MAP kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1772-1777.	1.0	20
56	â€˜Reverseâ€™ Î±-ketoamide-based p38 MAP kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5456-5459.	1.0	11
57	Determination of log <i>D</i> via Automated Microfluidic Liquid-Liquid Extraction. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5140-5142.	2.9	35
58	Rapid Multistep Synthesis of 1,2,4-Oxadiazoles in a Single Continuous Microreactor Sequence. <i>Journal of Organic Chemistry</i> , 2008, 73, 7219-7223.	1.7	73
59	Fragment-Based Design of Small Molecule X-Linked Inhibitor of Apoptosis Protein Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7111-7118.	2.9	53
60	Small Molecules Can Selectively Inhibit Ephrin Binding to the EphA4 and EphA2 Receptors. <i>Journal of Biological Chemistry</i> , 2008, 283, 29461-29472.	1.6	123
61	HTS Identifies Novel and Specific Uncompetitive Inhibitors of the Two-Component NS2B-NS3 Proteinase of West Nile Virus. <i>Assay and Drug Development Technologies</i> , 2007, 5, 737-750.	0.6	95
62	Preclinical Studies of Celestrol and Acetyl Isogambogic Acid in Melanoma. <i>Clinical Cancer Research</i> , 2007, 13, 6769-6778.	3.2	89
63	A Surprising Dipolar Cycloaddition Provides Ready Access to Aminoglycosides. <i>Journal of the American Chemical Society</i> , 2004, 126, 8356-8357.	6.6	63
64	Stereo- and regiospecific formation of a highly functionalized bridgehead tricyclic sultam. <i>Tetrahedron Letters</i> , 2002, 43, 4407-4409.	0.7	4